D
Douglas Brand
Researcher at Institute of Cancer Research
Publications - 22
Citations - 529
Douglas Brand is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 6, co-authored 14 publications receiving 248 citations. Previous affiliations of Douglas Brand include The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy
A. Pathmanathan,A. Pathmanathan,Helen McNair,Maria A. Schmidt,Maria A. Schmidt,Douglas Brand,Douglas Brand,Louise Delacroix,Cynthia L. Eccles,Cynthia L. Eccles,A. Gordon,T. Herbert,Nicholas van As,Nicholas van As,Robert Huddart,Robert Huddart,Alison Tree,Alison Tree +17 more
TL;DR: Therapeutic radiographer prostate contours are more accurate, show less interobserver variability and are more confidently and quickly outlined on MRI compared to CT, particularly using T2*W MRI.
Journal ArticleDOI
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Alison Tree,Peter Ostler,H. van der Voet,William C. Cho,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,John G. Armstrong,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,A. Duffton,Douglas Brand,D. Henderson,Kirsty Morrison,Stephanie Brown,Julia Pugh,Stephanie Burnett,Muneeb Mahmud,Victoria Hinder,O. Naismith,Emma Hall,Nicholas van As +27 more
TL;DR: PACE-B as discussed by the authors , a randomized trial of conventional fractionated or moderately hypofractionated radiotherapy versus Stereotactic Body Radiotherapy (SBRT), was conducted at 35 hospitals in the UK, Ireland, and Canada.
Journal ArticleDOI
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Anna Wilkins,Anna Wilkins,O. Naismith,Douglas Brand,Katie Fernandez,Emma Hall,David P. Dearnaley,Sarah L. Gulliford +7 more
TL;DR: Dose constraints differed between symptoms, indicating potentially different pathogenesis of radiation-induced side effects and may reduce bowel symptoms post-radiotherapy.
Journal ArticleDOI
PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
Nicholas van As,Douglas Brand,Alison Tree,Peter Ostler,William Chu,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander S. Martin,John Staffurth,Stephanie Brown,Stephanie Burnett,A. Duffton,Clare Griffin,Vicki Hinder,Kirsty Morrison,O. Naismith,Emma Hall +18 more
TL;DR: Key toxicity outcomes were worst grade 2+ Radiation Therapy Oncology Group (RTOG) genitourinary (GU) and gastrointestinal (GI) acute toxicities, compared by Chi-square test with alpha 0.05 divided between the two measures.